Trends and Development Bottleneck Analysis of Gene Editing Technology

doi:10.13523/j.cb.20181214

China Biotechnology

2018, Vol. 38

Issue (12): 113-122 DOI: 10.13523/j.cb.20181214

Orginal Article

Trends and Development Bottleneck Analysis of Gene Editing Technology

XU Li,WANG Yue,YAO Chi-yuan,XU Ping(

)

Shanghai Information Center of Life Sciences,Shanghai Information Center for Life Sciences,CAS,Shanghai 200031,China

Download:

HTML

PDF(940KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

Gene editing technology has spurred a global upsurge. In particular, CRISPR technology has become the most promising genome editing technology, and has rapidly achieved applications in livestock breeding, biomedical research and development, and related clinical trials have been carried out. Its development has driven the new direction of the development of the bio-industry, which has given birth to huge social and economic values. The current industrial structure has taken shape. China has always attached great importance to genetic editing, and has closely followed the pace of international development in scientific research and achieved a series of breakthrough results. At the same time, China has already reached the international leading level in the field of application of gene editing such as the construction of large animal models and clinical trials for disease treatment. In the future, China still needs to further promote technological innovation, seize international discourse rights in this field, and optimize the policy environment to ensure rapid and orderly development of the downstream applications of our country’s gene editing technology.

Key words： Gene editing technology Commercial application Industrial pattern

Received: 17 July 2018 Published: 10 January 2019

ZTFLH:

Q78

Corresponding Authors: Ping XU E-mail: xuping@sibs.ac.cn

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Li
	WANG Yue
	YAO Chi-yuan
	XU Ping

Cite this article:

XU Li, WANG Yue, YAO Chi-yuan, XU Ping. Trends and Development Bottleneck Analysis of Gene Editing Technology. China Biotechnology, 2018, 38(12): 113-122.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20181214 OR https://manu60.magtech.com.cn/biotech/Y2018/V38/I12/113

Table 1 Clinical trials using gene editing technology

Fig.1 Organizations of patent applications for gene editing technology in 2008-2017

Fig.2 Industry chain of gene editing technology

Table 2 Main companies for application of gene editing technology in breeding

公司名称	成立时间	国家	创始人	采用技术	在研项目	上市/融资情况
Editas Medicine	2013年	美国	张锋,Jennifer Doudna,George Church等	CRISPR-cas9	LCA等罕见眼疾、肝癌、肺癌、白血病、肌肉疾病	纳斯达克上市,最早IPO基因编辑公司,A轮融资4300万美元,B轮融资1.2亿美元
Intellia Therapeutics	2014年	美国	Jennifer Doudna	CRISPR-cas9	白血病、癌症、转甲状腺素蛋白淀粉样变性、α1-抗胰蛋白酶缺乏症和乙肝病毒、造血干细胞相关疾病	2016年5月纳斯达克上市,第二家IPO基因编辑公司,2014年,A轮融资100万美元,2015年9月, B轮融资7000万美元
CRISPR Therapeutics	2013年	瑞士	Emmanuelle Charpentier	CRISPR-cas9	囊肿性纤维化、失明、血液病及先天性心脏病	纳斯达克上市,第三家IPO基因编辑公司
Caribou Biosciences	2011年	美国	Jennifer Doudna等	CRISPR-cas9	多种疾病	融资4446万美元
Sangamo BioSciences	1995年	美国	Edward O. Lanphier II	ZFN	肝病、血友病、粘多糖累积症	纳斯达克上市
Exonics Therapeutics	2017年	美国	Eric Olson	CRISPR-cas9	杜氏肌营养不良和其他神经肌肉疾病	融资4500万美元
Homology Medicines	2015年	美国	Saswati Chatterjee等	腺病毒AAV	CD34阳性疾病、囊性纤维化、杜氏肌营养不良症、镰状细胞贫血	融资1.27亿美元
Poseida Therapeutics	2015年	美国	George Church等	CAR-T+CRISPR	多发性骨髓瘤、前列腺癌和β-地中海贫血	融资5400万美元
LogicBio Therapeutics	2016年	美国	Tomer Kariv和Mark Kay	腺病毒AAV	儿童遗传性肝病	融资4900万美元
Cellectis	2000年	法国	Andre Choulika等	TALEN	癌症	纳斯达克上市欧交所上市
Agenovir	2014年	美国	Stephen Quake	CRISPR-cas9	宫颈癌肛门癌疣巨细胞病毒和 Ebstein-Barr 病毒感染等	融资上亿美元
eGenesis	2015年	美国	George Church和杨璐菡	CRISPR-cas9	异体器官移植	2017年3月获得3800万美元A轮融资,披露的总融资金额约4000万美元
Universal Cells	2013年	美国	David Russell	腺相关病毒rAAV	异体器官移植
Horizon Discovery	2007年	英国	Chris Torrance 和Alberto Bardelli	腺相关病毒rAAV	提供基因编辑细胞的技术服务	多伦多上市
Synthego	2012年	美国	Paul Dabrowski 和 Michael Dabrowski	CRISPR-cas9	基因编辑改进技术CRISPRevolution	融资4980万美元
Benchling	2012年	美国	Y Combinator孵化	开发基因编辑技术平台	生物技术平台的搜索工具	融资1300万美元

Table 3 Overview of key international companies of gene editing technology

Table 4 Overview of key Chinese companies of gene editing technology


[1]	Jinek M,Chylinski K,Fonfara I,et al.A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.Science,2012,337:816-821.

[2]	Cong L,Ran F A,Cox D,et al.Multiplex genome engineering using CRISPR/Cas systems.Science,2013,339(6121):819-823. doi: 10.1126/science.1229223

[3]	Komor A C,Kim Y B,Packer M S,et al.Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.Nature,2016,7630(533):420-424.

[4]	Gaudelli N M,Alexis C.Komor,Holly A.Rees,et al.Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage.Nature,2017,551:464-471.

[5]	Cox D B T,Gootenberg J S, Abudayyeh O O, et al.RNA editing with CRISPR-Cas13.Science,2017, 358(6366) :1019-1027. doi: 10.1126/science.aaq0180 pmid: 29070703

[6]	Li X S, Wang Y, Liu Y J, et al.Base editing with a Cpf1-cytidine deaminase fusion.Nature Biotechnology,2018,36:324-327.

[7]	Wang X,Li J N,Wang Y,et al.Efficient base editing in methylated regions with a human APOBEC3A-Cas9 fusion.Nature Biotechnology,2018.08.20 (Online). doi: 10.1038/nbt.4198

[8]	Charlesworth C T,Deshpande P S,Dever D P,et al.Identification of pre-existing adaptive immunity to Cas9 proteins in humans.BioRxiv, 2018,36:946-949

[9]	Haapaniemi E,Botla S,Persson J,et al.CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response.Nature Medicine,2018,24:927-930. doi: 10.1038/s41591-018-0049-z pmid: 29892067

[10]	Ihry R J,Worringer K A,Salick M R,et al.p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells.Nature Medicine,2018,24:939-946. doi: 10.1038/s41591-018-0050-6 pmid: 29892062

[11]	Adikusuma F,Piltz S,Corbett M A,et al.Large deletions induced by Cas9 cleavage.Nature,2018,560:E8-E9. doi: 10.1038/s41586-018-0380-z

[12]	Slaymaker I M,Gao L Y,Zetsche B,et al.Rationally engineered Cas9 nucleases with improved specificity.Science,2015,351(6268):84-88. doi: 10.1126/science.aad5227 pmid: 4714946

[13]	Kleinstiver B P,Pattanayak V,Prew M S,et al.High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.Nature,2016,529:490-495.

[14]	Ran F A,Cong L,Yan W X,et al.In vivo genome editing using Staphylococcus aureus Cas9.Nature,2015,520:186-191.

[15]	Liao H K,Hatanaka F,Toshikazu Araoka,et al.In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation.Cell,2017,171(7):1497-1507. doi: 10.1016/j.cell.2017.10.025 pmid: 29224783

[16]	Liu Y C,Zhan Y H,Chen Z C,et al.Directing cellular information flow via CRISPR signal conductors. Nature Methods, 2016,13:938-944. doi: 10.1038/nmeth.3994 pmid: 27595406

[17]	Zuo E W,Huo X N,Yao X,et al.CRISPR/Cas9-mediated targeted chromosome elimination. Genome Biology, 2017,18:224. doi: 10.1186/s13059-017-1354-4 pmid: 29178945

[18]	Zetsche B,Gootenberg J S,Abudayyeh O O,et al.Cpf1 is a single RNA-Guided endonuclease of a class 2 CRISPR-Cas system.Cell,2015,163(3):759-771. doi: 10.1016/j.cell.2015.09.038 pmid: 26422227

[19]	Burstein D,Harrington L B,Strutt S C,et al.New CRISPR-Cas systems from uncultivated microbes.Nature,2017,542:237-241. doi: 10.1038/nature21059 pmid: 28005056

[20]	Abudayyeh O O,Gootenberg J S,Konermann S,et al.C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector.Science,2016,353(6299):aaf5573. doi: 10.1126/science.aaf5573 pmid: 27256883

[21]	Smargon A A,Cox D B T,Pyzocha N K,et al.Cas13b is a type VI-B CRISPR-associated RNA-guided Rnase differentially regulated by accessory proteins Csx27 and Csx28.Molecular Cell,2017,65(4):618-630. doi: 10.1016/j.molcel.2016.12.023 pmid: 5432119

[22]	Hu J H,Miller S M,Geurts M H,et al.Evolved Cas9 variants with broad PAM compatibility and high DNA specificity.Nature,2018,556:57-63. doi: 10.1038/nature26155 pmid: 29512652

[23]	Konermann S,Lotfy P,Brideau N J,et al.Transcriptome engineering with RNA-Targeting type VI-D CRISPR effectors.Cell,2018,173(3):665-676. doi: 10.1016/j.cell.2018.02.033 pmid: 29551272

[24]	Zetsche B,Heidenreich M,Mohanraju P,et al.Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array.Nature Biotechnology,2017,35(1):31-34. doi: 10.1038/nbt.3737 pmid: 27918548

[25]	Liu L,Li X Y,Wang J Y,et al.Two distant catalytic sites are responsible for C2c2 RNase activities.Cell,2017,168:1-2.

[26]	Liu L,Li X Y,Ma J,et al.The molecular architecture for RNA-guided RNA cleavage by Cas13a.Cell,2017,170(4):714-726. doi: 10.1016/j.cell.2017.06.050 pmid: 28757251

[27]	Levasseur A,Bekliz M,Chabrière E,et al.MIMIVIRE is a defence system in mimivirus that confers resistance to virophage.Nature,2016,531:249-252. doi: 10.1038/nature17146 pmid: 26934229

[28]	Nishida K,Arazoe T,Yachie N,et al.Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems.Science,2016,353(6305):aaf8729.

[29]	Xu S,Cao S S,Zou B J,et al.An alternative novel tool for DNA editing without target sequence limitation: the structure-guided nuclease.Genome Biology,2016,17:186. doi: 10.1186/s13059-016-1038-5 pmid: 27634179

[30]	Xu W,Liu Y C,Liu Y L,et al.Artificial small RNA for sequence specific cleavage of target RNA through RNase III endonuclease Dicer.Oncotarget,2016,7(34):54549-54554. doi: 10.18632/oncotarget.9582 pmid: 27231846

[31]	Shan Q W,Wang Y P,Li J,et al.Targeted genome modification of crop plants using a CRISPR-Cas system.Nature Biotechnology,2013,31:686-688. doi: 10.1038/nbt.2650 pmid: 23929338

[32]	Bassuk A G,Zheng Z,Li Y,et al.Precision medicine: genetic repair of retinitis pigmentosa in patient-derived stem cells.Scientific Reports,2016,6:19969. doi: 10.1038/srep19969 pmid: 4728485

[33]	Nelson C E,Hakim C H,Ousterout D G,et al.In vivo genome editing improves muscle function in a mouse model of duchenne muscular dystrophy.Science,2016,351(6271):403-407.

[34]	Chen Z H,Yu Y P,Zuo Z H,et al.Targeting genomic rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene.Nature Biotechnology,2017,35:543-550. doi: 10.1038/nbt.3843 pmid: 28459452

[35]	Kaminski R,Chen Y L,Fischer T,et al.Elimination of HIV-1 genomes from human t-lymphoid cells by CRISPR/Cas9 gene editing.Scientific Reports,2016,6,Article number: 22555.

[36]	Yang L H,Zhou X Y,Gang Wang,et al.Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9.Science,2017,357(6357):1303-1307. doi: 10.1126/science.aan4187 pmid: 28798043

[37]	Liang P P,Xu Y W,Zhang X Y,et al.CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes.Protein & Cell,2015,6(5):363-372. doi: 10.1007/s13238-015-0153-5 pmid: 25894090

[38]	Ma H,Marti-Gutierrez N,Sang-Wook P,et al.Correction of a pathogenic gene mutation in human embryos.Nature,2017,548:413-419. doi: 10.1038/nature23305 pmid: 28783728

[39]	Niu Y Y,Shen B,Cui Y Q,et al.Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos.Cell,2014,156(4):836-843. doi: 10.1016/j.cell.2014.01.027

[1]	CHEN Xin-jie,QIAN Zhi-lan,LIU Qi,ZHAO Qing,ZHANG Yuan-xing,CAI Meng-hao. *Modification of Aromatic Amino Acid Synthetic Pathway in Pichia pastoris* to Produce Cinnamic Acid and ρ-Coumaric Acid**[J]. China Biotechnology, 2021, 41(10): 52-61.

[2]	WANG Wei-dong,DU Jia-ru,ZHANG Yun-shang,FAN Jian-ming. The Application of CRISPR/Cas9 in the Treatment of Human Virus Infection-Related Diseases[J]. China Biotechnology, 2020, 40(12): 18-24.

[3]	XU Ying-yong. Current Status and Challenges of Gene Therapy Products[J]. China Biotechnology, 2020, 40(12): 95-103.

[4]	WANG Yue,MU Yan-shuang,LIU Zhong-hua. Progress of CRISPR/Cas Base Editing System[J]. China Biotechnology, 2020, 40(12): 58-66.

[5]	LEI Hai-ying,ZHAO Qing-song,BAI Feng-lin,SONG Hui-fang,WANG Zhi-jun. *Identification of Developing-related Gene ZmCen* Using CRISPR/Cas9 in Maize**[J]. China Biotechnology, 2020, 40(12): 49-57.

[6]	XUE Rui,YAO Lin,WANG Rui,LUO Zheng-shan,XU Hong,LI Sha. Advances and Applications of Recombinant Mussel Foot Proteins[J]. China Biotechnology, 2020, 40(11): 82-89.

[7]	CHEN Qing-yu,WANG Xian-zhong,ZHANG Jiao-jiao. Application of Gene Technology in the Treatment of Type 2 Diabetes Mellitus[J]. China Biotechnology, 2020, 40(11): 73-81.

[8]	HE Xiu-juan,HU Feng-zhi,LIU Qiu-li,LIU Yu-ping,ZHU Ling,ZHENG Wen-yun. CRISPR / Cas9 Gene Editing of QSOX1 in Breast Cancer Cells and Its Effect on the Proliferation and Invasion[J]. China Biotechnology, 2020, 40(11): 1-9.

[9]	LV Yi-fan,LI Geng-dong,XUE Nan,LV Guo-liang,SHI Shao-hui,WANG Chun-sheng. Prokaryotic Expression, Purification of LbCpf1 Protein Gene and in Vitro Cleavage Activity Assay[J]. China Biotechnology, 2020, 40(8): 41-48.

[10]	ZHANG Bao-hui,XIONG Hua-long,ZHANG Tian-ying,YUAN Quan. Research Progress on Vesicular Stomatitis Virus-based Oncolytic Virotherapy[J]. China Biotechnology, 2020, 40(6): 53-62.

[11]	WU Rui-jun,LI Zhi-fei,ZHANG Xin,PU Run,AO Yi,SUN Yan-rong. Development and Prospect of Antibody Drugs for SARS-CoV-2[J]. China Biotechnology, 2020, 40(5): 1-6.

[12]	LIU Di,ZHANG Hong-chun. Advances in Genetically Engineered Animal Models of Chronic Obstructive Pulmonary Disease[J]. China Biotechnology, 2020, 40(4): 59-68.

[13]	CHENG Ping,ZHANG Yang-zi,MA Xuan,CHEN Xu,ZHU Bao-qing,XU Wen-tao. Properties and Applications of Stimuli-Responsive DNA Hydrogels[J]. China Biotechnology, 2020, 40(3): 132-143.

[14]	GUO Sheng-nan, LI Xin-xiao, WANG Feng, LIU Kun-mei, DING Na, HU Qi-kuan, SUN Tao. *Establishment and Identification of the Neocortex and Hippocampus GABRG2* Knockout Mice and Its Preliminary Study in Generalized Epilepsy with Febrile Seizures Plus**[J]. China Biotechnology, 2020, 40(3): 9-20.

[15]	GUO Jing,HOU Zhan-ming. Folpcs1 Is Responsible for Asexual Reproduction and Vegetative Growth in Fusarium oxysporum f. sp. Lini.[J]. China Biotechnology, 2020, 40(3): 48-64.

Viewed

Full text

Abstract

Cited

Shared

Discussed